TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15922813
Drug: Adjustable maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable maintenance dosing of formoterol/budesonide (FOR/BUD) 6/200 microg BID
Study: 15922813
Drug: Stable dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable dosing of SAL/FP
Study: 15922813
Drug: Adjustable maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable maintenance dosing of FOR/BUD
Study: 12890374
Drug: Heliox-driven beta(2)-agonist
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heliox-driven beta(2)-agonist therapy (Berotec)
Study: 8886564
Drug: HOMA model
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA model assessment of insulin resistance (IR) and insulin secretion from fasting glucose and insulin concentrations.
Study: 8886564
Drug: HOMA model
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOMA model assessment of insulin secretion.
Study: 1886349
Drug: Naftidrofuryl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (2 x 200 mg/day)
Study: 6682324
Drug: Carteolol 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol 15 mg/day
Study: 31060979
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m2
Study: 31060979
Drug: Guadecitabine 90
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 90 mg/m2
Study: 31060979
Drug: Guadecitabine 60
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine 60 mg/m2 and 90 mg/m2
Study: 26502953
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (no treatment)
Study: 17437473
Drug: 0.1 mL
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mL intradermally at two sites on one day
Study: 4846329
Drug: Centrally stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally stimulant and depressant drugs
Study: 30689494
Drug: Untailored intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untailored intervention (iPad-based Vaccine Information Sheet)
Study: 29072001
Drug: Eye-acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye-acupuncture therapy
Study: 18438851
Drug: Step-up therapy
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up therapy
Study: 18438851
Drug: Parallel triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel triple therapy
Study: 9217034
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and hormone therapy
Study: 3302112
Drug: Cinnarizine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine (75 mg bd)
Study: 31128568
Drug: Intranasal vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal vasopressin
Study: 22972879
Drug: Cystine (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystine (700 mg) and theanine (280 mg) administered for 10 days (4 days before to 5 days after surgery)
Study: 20601414
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g intravenous)
Study: 18211575
Drug: Topical wound
Normalized name: Solox Gel Silver Antimicrobial Topical Wound Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical wound treatments
Study: 14563183
Drug: Methotrexate (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (i.v. 25 mg/week for 3 months, then oral 25 mg/week for 3 months)
Study: 14563183
Drug: Azathioprine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (oral 2 mg/kg per day for 6 months)
Study: 8720610
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg acipimox
Study: 2944997
Drug: Zomepirac 100
Normalized name: zomepirac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac 100 mg
Study: 7586360
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (uncoated circuits with full heparin dose; n = 17)
Study: 8994317
Drug: TBE-vaccine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE-vaccine (0.4 microgram)
Study: 8994317
Drug: TBE-vaccine (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE-vaccine (0.75 microgram)
Study: 8994317
Drug: TBE-vaccine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBE-vaccine (1.5 micrograms)
Study: 1479106
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment (50 micrograms/gm) twice daily for 4 weeks
Study: 7924241
Drug: Group Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Therapy (GT)
Study: 29905824
Drug: 4.4 g
Normalized name: ALUMINUM CHLOROHYDRATE 4.4 g in 1 mg BUCCAL EMULSION [Antiperspirant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.4 g milk protein + 4.4 g rice protein/d
Study: 24568963
Drug: Low-dose clonidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose clonidine
Study: 20148772
Drug: Entropy-guided sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entropy-guided sevoflurane administration
Study: 20148772
Drug: Standard practice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard practice sevoflurane administration
Study: 19402358
Drug: PMT-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMT-based treatment
Study: 12355675
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of psychotherapy and medications
Study: 10514397
Drug: Topical estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical estrogen patch
Study: 1742002
Drug: Adjusted-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose heparin
Study: 30280443
Drug: Parental drug
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental drug use
Study: 26387692
Drug: Modified protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified protocol (2 mg per kg body weight given in a single infusion over 2 h, repeated every 4 months)
Study: 26387692
Drug: Standard protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protocol (1 mg per kg body weight over 4 h on 3 successive days, repeated every 4 months)
Study: 18571082
Drug: Data-injection ring
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data-injection ring system
Study: 18571082
Drug: No data-injection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No data-injection system
Study: 16025732
Drug: Direct hypnotic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct hypnotic procedure using the Harvard Group Scale of Hypnotic Susceptibility: Form A (HGSHS:A)
Study: 16025732
Drug: Indirect hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indirect hypnotic procedure using the Alman‐Wexler Indirect Hypnotic Susceptibility Scale (AWIHSS)
Study: 12064813
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg/day
Study: 10495686
Drug: Metoprolol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol administration at an initial dose of 25 mg/day (12.5 mg for class III-IV patients), increased to a maximum of 200 mg/day
Study: 1773685
Drug: Decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision support system for insulin-dose adjustment
Study: 21284343
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of arginine (12.3 g per day)
Study: 25855918
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of arginine (18.9 g per day)
Study: 24622416
Drug: 6.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg/kg ATG over four days
Study: 24622416
Drug: 6.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.5 mg/kg ATG
Study: 18661120
Drug: eMPC advised
Approvals — FDA: no, EMA: no, PMDA: no
Description: eMPC advised insulin infusion
Study: 15202162
Drug: Granisetron (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (single oral dose)
Study: 15202162
Drug: Ondansetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (2 intravenous doses of 0.15 mg/kg followed by 1 oral dose)
Study: 2813482
Drug: Cocaine infusion
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine infusion
Study: 2563317
Drug: Pancuronium 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.15 mg.kg‐1
Study: 26747037
Drug: Daily smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smoking
Study: 16606815
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg/d)
Study: 19467365
Drug: Ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ingenol mebutate gel 0.05% for 2 or 3 days
Study: 19467365
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel for 3 days
Study: 16323095
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg daily for 7-14 days)
Study: 16323095
Drug: Levofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (500 mg daily for 7-14 days)
Study: 9008458
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg
Study: 10190078
Drug: Intensive course
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive course of high fractional X‐ray therapy (cumulative dose up to 25 Gy) with direct protracted endolymphatic chemotherapy with 5‐fluorouracil (5‐FU) instilled in 600 mg/m2 each day before operation, up to a cumulative dose of 5 g.
Study: 10190078
Drug: Ukrain as
Normalized name: Ukrain cation
DrugBank: Ukrain cation (DB17150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain as monotherapy, 10 mg each second day before operation (up to a cumulative dose of 60 mg) and a total of 40 mg after surgical intervention, with repeated courses (100 mg/per course) 6 months after surgical operation.
Study: 8298540
Drug: Exploratory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exploratory therapy
Study: 2245269
Drug: Prescriptive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptive therapy
Study: 15507176
Drug: Trastuzumab added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab added to chemotherapy
Study: 28532387
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model with 4 clinical covariates, 98 biomarkers, and 24 biomarker-by-treatment interactions
Study: 26380442
Drug: Jiangyabao serial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiangyabao serial drugs combined with Western medicine (WM)
Study: 26380442
Drug: Simulative agents
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulative agents of Jiangyabao serial drugs combined with Western medicine (WM)
Study: 26380442
Drug: Combined hypotensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hypotensive treatment program with Nifedipine Sustained Release Tablet and Hydrochlorothiazide
Study: 20333384
Drug: HA-Irinotecan (HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-Irinotecan (HA 1,000 mg/m(2) and irinotecan at 350 mg/m(2))
Study: 20333384
Drug: irinotecan (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan (350 mg/m(2))
Study: 12508081
Drug: Triiodothyronine (T3)
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triiodothyronine (T3) and hydrocortisone supplementation (6 micro g.kg(‐1).d(‐1) of T3 with 1 mg.kg(‐1).d(‐1) of hydrocortisone)
Study: 10335931
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg p.o. twice a day
Study: 8915757
Drug: Systemic rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic rIL-2 infusion following intrathecal treatment
Study: 8915757
Drug: Clinical condition
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical condition post-treatment
Study: 387070
Drug: Co-trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (800 mg sulphamethoxazole and 160 mg trimethoprim) administered as a single 10 ml intravenous infusion during surgery.
Study: 387070
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as a single 10 ml intravenous infusion during surgery.
Study: 28864487
Drug: Pap screening
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Hyco-pap]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pap screening (HCP-administered)
Study: 2896826
Drug: Two-component vaccine
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component vaccine containing formaldehyde detoxified lymphocytosis promoting factor (LPF) and filamentous haemagglutinin
Study: 2896826
Drug: Placebo (vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vaccine solvent)
Study: 28835228
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100,000 International Units cholecalciferol monthly)
Study: 25462419
Drug: Twice-daily HF-rTMS
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily HF-rTMS (10 Hz) over the left dorsolateral prefrontal cortex for 2 weeks (60,000 pulses)
Study: 23619819
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg meloxicam tablet
Study: 23619819
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg meloxicam suspension
Study: 21073813
Drug: Intercept oral
Normalized name: INTERCEPTOR Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercept oral specimen collection device
Study: 11459288
Drug: Leukocyte-depleted erythrocyte
Normalized name: erythrocytes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte-depleted erythrocyte suspensions (LD-SAGM)
Study: 11459288
Drug: Non-leukocyte-depleted erythrocyte
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-leukocyte-depleted erythrocyte suspensions (SAGM)
Study: 7870725
Drug: Local applications
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local applications of rifampicin and dimexide solutions
Study: 24242334
Drug: Intravaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal progesterone implant between days 3 and 7 following fixed-time artificial insemination (FTAI)
Study: 19157346
Drug: Tropisetron plus
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron plus subhypnotic propofol infusion
Study: 15034285
Drug: Low-dose omeprazole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose omeprazole (L-OMP: 10 mg, q.d.)
Study: 15034285
Drug: Standard-dose ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ranitidine (S-H2RA: 150 mg, b.i.d.)
Study: 3042835
Drug: rt-PA (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (70 mg with an initial bolus of 10 mg)
Study: 24968970
Drug: GTx‐758 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTx‐758 1000 mg/d
Study: 24968970
Drug: GTx‐758 2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTx‐758 2000 mg/d
Study: 24002501
Drug: Cabozantinib (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (140 mg per day)
Study: 24013610
Drug: Riluzole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100 mg/day)
Study: 6790966
Drug: Heparin-Dihydergot 2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-Dihydergot 2500
Study: 6790966
Drug: Conventional low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional low dose heparin regimen
Study: 25022109
Drug: Domperidone, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone, 10 mg orally, three times a day for 4 sessions (5 days each session)
Study: 23063071
Drug: Onartuzumab (MetMAb)
Normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onartuzumab (MetMAb) plus erlotinib (150 mg oral daily)
Study: 23063071
Drug: Erlotinib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib alone (150 mg oral daily)
Study: 19039022
Drug: Cpn10 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cpn10 (5 mg or 10 mg weekly for 12 weeks)
Study: 17329479
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of memantine
Study: 23384372
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of memantine
Study: 10450451
Drug: Intradermal (i.d.)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (i.d.) administration of one-fifth dose of purified Vero-cell rabies vaccine (PVRV) with routine DTP-IPV vaccines (2, 3, 4 months)
Study: 7846538
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination chemotherapy (cyclophosphamide/doxorubicin/vincristine)
Study: 2129649
Drug: Colestipol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 2.5 g b.d.
Study: 2129649
Drug: Colestipol 5
Normalized name: colestipol 5 g oral granule for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 5 g b.d.
Study: 2129649
Drug: Colestipol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol 7.5 g b.d.
Study: 6171687
Drug: Trimazosin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimazosin (300 mg single dose)
Study: 22289389
Drug: Microwave energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microwave energy device treatment
Study: 18431084
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical training and nutritional intervention
Study: 18298870
Drug: No milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No milk supplement
Study: 16117978
Drug: FF‐muG 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF‐muG 130 mg with food
Study: 16117978
Drug: FF‐muG 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF‐muG 130 mg without food
Study: 15247553
Drug: Atazanavir 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 400 mg once daily
Study: 14685054
Drug: Atazanavir 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 600 mg once daily
Study: 14685054
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg twice a day
Study: 10863994
Drug: High-salt diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-salt diet (HS; normal food plus NaCl 100 mg/kg per day)
Study: 10863994
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral water load of 1500 ml
Study: 1625504
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m. for four weeks
Study: 1625504
Drug: Omeprazole-treated patients
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-treated patients re-examined 15 days after drug withdrawal
Study: 6613908
Drug: Fatty fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty fish consumption (100 g or more at least twice a week for 3 months)
Study: 24365194
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C infusion (3-g infusion within 6 hours before PCI)
Study: 15668427
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg testosterone enanthate plus 1 mg daily of anastrozole (AT group, n = 19)
Study: 15668427
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection and placebo pill (placebo group, n = 21)
Study: 23207959
Drug: Solifenacin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin (5 mg once daily)
Study: 24465443
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg daily with lopinavir/ritonavir
Study: 24465443
Drug: Rifabutin 150
Normalized name: rifabutin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin 150 mg three times per week with lopinavir/ritonavir
Study: 24465443
Drug: Rifabutin 300
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifabutin 300 mg alone
Study: 17696277
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg prednisolone daily (n = 34)
Study: 16181540
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract injection (GB)
Study: 9206242
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone
Study: 16159821
Drug: Heparin-coated CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated CPB circuits
Study: 1297896
Drug: New chewable,
Approvals — FDA: no, EMA: no, PMDA: no
Description: New chewable, buffered ASA tablet formulation
Study: 30664617
Drug: Bupropion-escitalopram combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion-escitalopram combination
Study: 29522941
Drug: Venlafaxine-mirtazapine combination
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine-mirtazapine combination